treatment of malignant ascites

Written By web share on mardi 28 avril 2020 | 11:09

Anti - cancer research in 2019 - Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer

Abstract. Background: Malignant ascites is a frequent problem for ovarian carcinoma patients. Typical symptomssuch as abdominal pain, nausea and dyspneareduce qualityof life. In this study, different treatment options formalignant ascites due to ovarian carcinoma were sought. Materials and Methods: Articles and reviews found inPubMed and reference books were evaluated and compared to each other. Results: Many treatment options exist. Current treatment options include paracentesis, intraperitonealchemotherapy and therapy using intraperitoneal tumornecrosis factor alpha for example. Compared to otherreviews, catumaxomab, a new antibody, was presented and the treatment options were focused on ovarian carcinoma patients. All these methods are palliative. Conclusion: Thetreatment of malignant ascites keeps a demanding difficultyand requires further study especially on progressive freesurvival and overall survival. Paracentesis and systemictherapy with a later effect are recommendedat the moment.Catumaxomab is the only medication that could achieve animprovement. Ovarian cancer (OC) is a rare tumor type. One to twopercent of women will be diagnosed with OC whichmakes it the seventh most common type of cancer inwomen . The incidence rate in Germany isapproximately 8,000 per year , with mostly womenbetween 70 and 80 years affected . Usually OC is notdiagnosed in an early stage so that only 30-40% of thepatients survive the first five years after their initialdiagnosis .... read more by downloading this document.